Inhibikase Therapeutics (IKT) Earnings Date, Estimates & Call Transcripts → Time is Running Out - June 25th Deadline Approaching! (From Paradigm Press) (Ad) Free IKT Stock Alerts $1.69 +0.03 (+1.81%) (As of 06/7/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Earnings SummaryUpcoming Earnings DateAug. 12EstimatedActual EPS (May. 15) -$0.73 Beat By $0.06 Consensus EPS (May. 15) -$0.79 Get Inhibikase Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for IKT and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueIKT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.IKT Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Augury ResearchBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is currently auctioning off CITGO (the winning bid will be announced on July 22nd).Get all the details here. Inhibikase Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($0.79)($0.79)($0.79)Q2 20241($0.58)($0.58)($0.58)Q3 20241($0.37)($0.37)($0.37)Q4 20241($0.37)($0.37)($0.37)FY 20244($2.11)($2.11)($2.11)IKT Earnings Date and InformationInhibikase Therapeutics last issued its earnings data on May 15th, 2024. The reported ($0.73) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.06. Inhibikase Therapeutics has generated ($3.33) earnings per share over the last year (($3.33) diluted earnings per share). Earnings for Inhibikase Therapeutics are expected to grow in the coming year, from ($1.87) to ($1.47) per share. Inhibikase Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 12th, 2024 based off prior year's report dates.Read More Inhibikase Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/12/2024(Estimated)------- 5/15/2024Q1 2024($0.79)($0.73)+$0.06($0.73)--3/27/2024Q4 2023($0.78)($0.63)+$0.15($0.63)-- 11/14/2023Q3 2023($1.12)($0.86)+$0.26($0.86)-$0.08 million8/14/2023Q2 2023($0.92)($1.11)($0.19)($1.11)-$0.12 million 5/15/2023Q1 2023($0.90)($0.96)($0.06)($0.16)-$0.07 million3/31/2023Q4 2022-($1.02)($1.02)($0.17)-$0.06 million Get the Latest News and Ratings for IKT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/14/2022Q3 2022-($1.08)($1.08)($0.18)-$0.01 million8/12/2022Q2 2022-($1.08)($1.08)($0.18)-$0.01 million5/16/2022Q1 2022-($1.08)($1.08)($0.18)-$0.05 million 3/31/2022Q4 2021-($1.20)($1.20)($0.20)--11/15/2021Q3 2021($0.84)($1.08)($0.24)($0.18)-$0.33 million8/16/2021Q2 2021($2.28)($1.32)+$0.96($0.22)-$1.36 million5/17/2021Q1 2021-($1.56)($1.56)($0.26)-$1.41 million4/1/2021Q4 2020-($0.90)($0.90)($0.15)-$0.17 million Inhibikase Therapeutics Earnings - Frequently Asked Questions When is Inhibikase Therapeutics's earnings date? Inhibikase Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 12th, 2024 based off last year's report dates. Learn more on IKT's earnings history. Did Inhibikase Therapeutics beat their earnings estimates last quarter? In the previous quarter, Inhibikase Therapeutics (NYSE:IKT) reported ($0.73) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.79) by $0.06. Learn more on analysts' earnings estimate vs. IKT's actual earnings. How much revenue does Inhibikase Therapeutics generate each year? Inhibikase Therapeutics (NYSE:IKT) has a recorded annual revenue of $260,000.00. How much profit does Inhibikase Therapeutics generate each year? Inhibikase Therapeutics (NYSE:IKT) has a recorded net income of -$19.03 million. IKT has generated -$3.33 earnings per share over the last four quarters. What is Inhibikase Therapeutics's EPS forecast for next year? Inhibikase Therapeutics's earnings are expected to grow from ($1.87) per share to ($1.47) per share in the next year. More Earnings Resources from MarketBeat Related Companies: ALGS Earnings Results ACHL Earnings Results CYTH Earnings Results QNCX Earnings Results NKGN Earnings Results SRZN Earnings Results ESLA Earnings Results INKT Earnings Results PLUR Earnings Results BCLI Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: CrowdStrike's Earnings: Consolidation and AI-Driven Growth The Most Upgraded Stocks After the Q1 Earnings Season ZIM Shipping Stock Forecast, Earnings Triggers a BuyAmerican Superconductor's Earnings Surge, Future Growth ExpectedHormel: A Potential Buy Despite Post-Earnings DeclineCanopy Growth’s Earnings: Profitability Despite Industry ShiftsAbercrombie & Fitch First Quarter Earnings Surge to New Heights This page (NYSE:IKT) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.